SS&C Technologies Holdings Inc. Common Stock vs Stryker Corporation — how do they compare? SS&C Technologies Holdings Inc. Common Stock trades at $82.08 (market cap $19.13B), while Stryker Corporation trades at $282 (market cap $108.38B). The key difference: Stryker Corporation is far larger — about 5.7× SS&C Technologies Holdings Inc. Common Stock's market cap, and SS&C Technologies Holdings Inc. Common Stock pays the higher dividend (1.47%). Which is the better fit depends on your goals — on Pluang, investors hold SS&C Technologies Holdings Inc. Common Stock for 0 Days and Stryker Corporation for 22 Days on average.
| SSNC | SYK | |
|---|---|---|
Market Cap | $19.13B | $108.38B |
Volume | 1,333,448 | 2,068,363 |
Sector | Technology | Health |
52-Week High | $89.62 | $388.35 |
52-Week Low | $62.05 | $269.75 |
Typical Hold Time | 0 Days | 22 Days |
Enterprise Value | $26.47B | $119.84B |
Dividend Yield | 1.47% | 1.25% |
Signals from Pluang's Aura AI — not financial advice
SSNC trades at $81.52, up 0.65% on the day, with a neutral technical signal. The company has consistently beaten earnings estimates in recent quarters (Q4 2025, Q1 2026, Q2 2026) and shows solid fundamentals, including a 13.16% net income margin and 12.73% ROE. Recent news highlights new client wins and AI-driven product enhancements, reinforcing its market position.
The outlook is positive, supported by strong analyst consensus (70.83% Buy rating) and a $91.50 price target, implying ~12% upside. Key risks include execution of growth initiatives and competitive pressures in the financial technology sector. The stock presents a compelling opportunity for investors seeking a fundamentally sound company with recurring revenue streams.
Stryker (SYK) trades at $282.63, showing minimal daily movement. The stock exhibits a neutral technical stance with mixed moving averages and oscillators. Fundamentally, SYK maintains strong profitability with a 14.43% net income margin and 16.51% ROE, though a P/E of 29.28 suggests a premium valuation. Recent news highlights ongoing legal scrutiny over a manufacturing issue disclosed in September 2026, which caused a significant price drop. Q3 2026 earnings are anticipated on October 29, 2026, following a mix of beats and misses in prior quarters.
The outlook for SYK is cautiously optimistic, supported by analyst consensus with a $365.89 price target and no sell ratings. Investment appeal lies in its solid cash flow and market position, but risks include legal investigations and persistent operational challenges. The stock's near-term direction will likely hinge on Q3 earnings results and clarity on the manufacturing issue resolution.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
SS&C Technologies Holdings, Inc. provides software and outsourced services for financial services and healthcare organizations, covering fund accounting, portfolio management, trading support, and regulatory reporting, and operates as a hedge fund and private equity administrator and mutual fund transfer agent.
Read more on SSNC →Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.
Read more on SYK →